Atezolizumab Can Now Be Used Frontline in Cisplatin-Ineligible Bladder Cancer
April 18th 2017The Food and Drug Administration (FDA) granted an accelerated approval to atezolizumab (Tecentriq) to be used as a frontline treatment for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma (mUC).